CL2018003349A1 - Combinación de anticuerpo anti-cd20, inhibidor selectivo de pelasa de p13, e inhibidor de btk para tratar trastornos proliferativos de células b. - Google Patents
Combinación de anticuerpo anti-cd20, inhibidor selectivo de pelasa de p13, e inhibidor de btk para tratar trastornos proliferativos de células b.Info
- Publication number
- CL2018003349A1 CL2018003349A1 CL2018003349A CL2018003349A CL2018003349A1 CL 2018003349 A1 CL2018003349 A1 CL 2018003349A1 CL 2018003349 A CL2018003349 A CL 2018003349A CL 2018003349 A CL2018003349 A CL 2018003349A CL 2018003349 A1 CL2018003349 A1 CL 2018003349A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibitor
- cells
- antibody
- combination
- proliferative disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662342822P | 2016-05-27 | 2016-05-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2018003349A1 true CL2018003349A1 (es) | 2019-03-15 |
Family
ID=60412660
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018003349A CL2018003349A1 (es) | 2016-05-27 | 2018-11-23 | Combinación de anticuerpo anti-cd20, inhibidor selectivo de pelasa de p13, e inhibidor de btk para tratar trastornos proliferativos de células b. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10966977B2 (enExample) |
| EP (1) | EP3463318A4 (enExample) |
| JP (1) | JP2019517485A (enExample) |
| KR (1) | KR20190015351A (enExample) |
| CN (1) | CN109640964A (enExample) |
| AU (1) | AU2017268839A1 (enExample) |
| BR (1) | BR112018074238A2 (enExample) |
| CA (1) | CA3024123A1 (enExample) |
| CL (1) | CL2018003349A1 (enExample) |
| EA (1) | EA201892284A1 (enExample) |
| IL (1) | IL263239A (enExample) |
| MX (1) | MX2018014577A (enExample) |
| SG (1) | SG11201810333UA (enExample) |
| WO (1) | WO2017205843A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3892302T3 (pl) | 2015-04-06 | 2024-03-11 | Janssen Pharmaceutica Nv | Kompozycje zawierające ibrutynib |
| KR102436875B1 (ko) * | 2017-12-08 | 2022-08-26 | 주식회사 보령 | Pi3 키나아제 억제제 및 bcl-2 억제제를 포함하는 조성물 |
| AU2019265019B2 (en) | 2018-05-11 | 2025-11-06 | Beam Therapeutics Inc. | Methods of substituting pathogenic amino acids using programmable base editor systems |
| KR20250125432A (ko) * | 2018-06-15 | 2025-08-21 | 얀센 파마슈티카 엔브이 | 이브루티닙을 포함하는 제형/조성물 |
| CN108743947B (zh) * | 2018-07-04 | 2020-12-15 | 复旦大学附属肿瘤医院 | 一种治疗b细胞淋巴瘤的药物组合物 |
| CN114127074A (zh) * | 2019-07-15 | 2022-03-01 | 庄信万丰股份有限公司 | 无定形乌帕拉尼单甲苯磺酸盐 |
| WO2022104150A1 (en) | 2020-11-12 | 2022-05-19 | Tg Therapeutics, Inc. | Triple combination to treat b-cell malignancies |
| EP4319771A4 (en) * | 2021-04-08 | 2025-01-01 | Artiva Biotherapeutics, Inc. | CANCER TREATMENT WITH NK CELLS AND AN ANTIBODY TARGETING HER2 |
| US11965032B1 (en) | 2022-06-01 | 2024-04-23 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11814439B1 (en) | 2022-06-01 | 2023-11-14 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11884740B1 (en) | 2022-06-01 | 2024-01-30 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
| US11807689B1 (en) | 2022-06-01 | 2023-11-07 | Tg Therapeutics, Inc. | Anti-CD20 antibody compositions |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| WO1999004705A1 (en) | 1997-07-25 | 1999-02-04 | Tsui Ban C H | Devices, systems and methods for determining proper placement of epidural catheters |
| FR2807767B1 (fr) | 2000-04-12 | 2005-01-14 | Lab Francais Du Fractionnement | Anticorps monoclonaux anti-d |
| FR2844455B1 (fr) | 2002-09-13 | 2007-12-14 | Lab Francais Du Fractionnement | Traitement des pathologies echappant a la reponse immune par des anticorps optimises |
| EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| FR2858235B1 (fr) | 2003-07-31 | 2006-02-17 | Lab Francais Du Fractionnement | Utilisation d'anticorps optimises en adcc pour traiter les patients faibles repondeurs |
| US7663057B2 (en) | 2004-02-19 | 2010-02-16 | Nanosolar, Inc. | Solution-based fabrication of photovoltaic cell |
| FR2879204B1 (fr) | 2004-12-15 | 2007-02-16 | Lab Francais Du Fractionnement | Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b. |
| US8543180B2 (en) | 2006-05-03 | 2013-09-24 | Covidien Lp | Method and apparatus for total hemoglobin measurement |
| PL2526933T3 (pl) | 2006-09-22 | 2015-08-31 | Pharmacyclics Llc | Inhibitory kinazy tyrozynowej Brutona |
| SG10201500895XA (en) | 2009-11-05 | 2015-04-29 | Rhizen Pharmaceuticals Sa | Chromen-4-one Derivatives As Kinase Modulators |
| CN109970742A (zh) | 2012-07-04 | 2019-07-05 | 理森制药股份公司 | 选择性PI3Kδ抑制剂 |
| EP3756686A1 (en) | 2012-11-02 | 2020-12-30 | TG Therapeutics Inc. | Combination of anti-cd20 antibody and pi3 kinase selective inhibitor |
| US10272083B2 (en) | 2014-01-21 | 2019-04-30 | Acerta Pharma B.V. | Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor |
| CA2942528A1 (en) | 2014-03-20 | 2015-09-24 | Pharmacyclics Inc. | Phospholipase c gamma 2 and resistance associated mutations |
| WO2015181728A1 (en) | 2014-05-27 | 2015-12-03 | Rhizen Pharmaceuticals Sa | Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations |
| AU2015300966A1 (en) | 2014-08-08 | 2017-02-16 | Janssen Pharmaceutica Nv | Bruton's tyrosine kinase inhibitor combinations and uses thereof |
| US20170224819A1 (en) * | 2014-08-11 | 2017-08-10 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor, a PI3K Inhibitor, a JAK-2 Inhibitor, and/or a CDK 4/6 Inhibitor |
-
2017
- 2017-05-26 EA EA201892284A patent/EA201892284A1/ru unknown
- 2017-05-26 CN CN201780032933.0A patent/CN109640964A/zh active Pending
- 2017-05-26 JP JP2018562232A patent/JP2019517485A/ja active Pending
- 2017-05-26 KR KR1020187037436A patent/KR20190015351A/ko not_active Ceased
- 2017-05-26 CA CA3024123A patent/CA3024123A1/en not_active Abandoned
- 2017-05-26 BR BR112018074238-4A patent/BR112018074238A2/pt not_active Application Discontinuation
- 2017-05-26 SG SG11201810333UA patent/SG11201810333UA/en unknown
- 2017-05-26 WO PCT/US2017/034855 patent/WO2017205843A1/en not_active Ceased
- 2017-05-26 MX MX2018014577A patent/MX2018014577A/es unknown
- 2017-05-26 EP EP17803731.3A patent/EP3463318A4/en not_active Withdrawn
- 2017-05-26 US US16/304,590 patent/US10966977B2/en not_active Expired - Fee Related
- 2017-05-26 AU AU2017268839A patent/AU2017268839A1/en not_active Abandoned
-
2018
- 2018-11-22 IL IL263239A patent/IL263239A/en unknown
- 2018-11-23 CL CL2018003349A patent/CL2018003349A1/es unknown
-
2021
- 2021-02-12 US US17/175,184 patent/US20210169878A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201810333UA (en) | 2018-12-28 |
| AU2017268839A1 (en) | 2018-11-29 |
| US10966977B2 (en) | 2021-04-06 |
| MX2018014577A (es) | 2019-05-20 |
| BR112018074238A2 (pt) | 2019-04-16 |
| EP3463318A1 (en) | 2019-04-10 |
| EA201892284A1 (ru) | 2019-08-30 |
| JP2019517485A (ja) | 2019-06-24 |
| CA3024123A1 (en) | 2017-11-30 |
| WO2017205843A1 (en) | 2017-11-30 |
| CN109640964A (zh) | 2019-04-16 |
| IL263239A (en) | 2018-12-31 |
| US20210169878A1 (en) | 2021-06-10 |
| EP3463318A4 (en) | 2020-01-01 |
| KR20190015351A (ko) | 2019-02-13 |
| US20190175592A1 (en) | 2019-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021003373A1 (es) | Nuevos inhibidores de egfr | |
| CO2021001893A2 (es) | Anticuerpos anti-gdf15, composiciones y métodos de uso | |
| CL2020000263A1 (es) | Conjugado de anticuerpo monoclonal contra bcma-fármaco. | |
| CO2021002954A2 (es) | Anticuerpos anti-αvβ8 y composiciones y usos de los mismos | |
| CO2020006900A2 (es) | Medios y método para preparar vectores virales y usos de los mismos | |
| CR20160500A (es) | Anticuerpos anti-ox40 y métodos de uso | |
| AR112048A1 (es) | Anticuerpos cd47 y métodos de uso de los mismos | |
| MX2018000778A (es) | Metodos para tratar trastornos mediados por hepcidinas. | |
| PE20150646A1 (es) | Metodos de tratamiento de una tauopatia | |
| UY37494A (es) | COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO | |
| MX2016013457A (es) | Inhibidores de mdm2 y metodos terapeuticos que utilizan el mismo. | |
| CO2018001149A2 (es) | Anticuerpos monoclonales contra bcma | |
| MX387295B (es) | Nueva forma de interleucina-33 (il33), formas mutadas de interleucina-33 (il33), anticuerpos, ensayos y métodos para usar los mismos. | |
| CR20190150A (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad, kits, y métodos | |
| CR20160257A (es) | Anticuerpos e inmunoconjugados anti-cd33 | |
| DOP2021000161A (es) | INHIBIDORES ESPECÍFICOS DEL COMPLEJO DE LTBP DE TGFß Y USOS DE LOS MISMOS | |
| CR20180605A (es) | Anticuerpos anti-cd40 y sus usos | |
| ES3063961T3 (en) | Cells for immunotherapy engineered for targeting antigen present both on immune cells and pathological cells | |
| MX2015005536A (es) | Tratamiento de canceres utilizando moduladores de las isoformas de pi3 cinasa. | |
| BR112018074238A2 (pt) | combinação de anticorpo anti-cd20, inibidor de p13 quinase-delta seletivo e inibidor de btk para tratar desordens proliferativas de células b | |
| MX2020003605A (es) | Manipulación del metabolismo de triptamina. | |
| MX2022007436A (es) | Inhibidores de la autotaxina y sus usos. | |
| UY35424A (es) | Xantinas sustituidas y métodos para su uso | |
| CL2016002419A1 (es) | Métodos para determinar la probabilidad de padecer cáncer de próstata que comprende inmunoensayos de antígenos específicos de próstata | |
| CL2019001522A1 (es) | Oligonucleótidos modificados para el tratamiento de una enfermedad poliquística renal. |